Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Vir Biotechnology in a report released on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz ...

In a report released on January 13, Faisal Khurshid from Leerink Partners reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report). The company’s shares closed yesterday at $54.16.

Leerink Partners analyst Andrew Berens maintained a Buy rating on Immunome (IMNM – Research Report) on January 13. The company’s shares closed yesterday at $9.38. Discover outperforming stocks ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 21.94% ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...